drugset / Trial / NCT06105684
Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II study aiming at evaluating capecitabine prospectively at a dose of 1000 mg once daily in patients with advanced breast cancer who are ≥60 years of age, or frail at any age, with a greater risk of complications and poorer outcomes with other treatments.
Timeline
- Start
- 2025-02-14
- Primary completion
- 2028-06
- Completion
- 2028-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg | Oral |